Crucell NV (CRXL) Up On Renewed Takeover Chatter
After trading lower earlier, Crucell NV (Nasdaq: CRXL) is up 1.5% now on resurfaced takeover chatter.
Johnson & Johnson (NYSE: JNJ), which announced a partnership with Crucell in September, is seen as a possible suitor. Other potential suitors include Sanofi-Aventis (NYSE: SNY), Novartis (NYSE: NVS) or Abbott Laboratories (NYSE: ABT).
Johnson & Johnson (NYSE: JNJ), which announced a partnership with Crucell in September, is seen as a possible suitor. Other potential suitors include Sanofi-Aventis (NYSE: SNY), Novartis (NYSE: NVS) or Abbott Laboratories (NYSE: ABT).
You May Also Be Interested In
- Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent
- DealReporter Says Diamond Foods (DMND) to Receive PIPE Investment from Oaktree; Shares Moving Higher
- Stocks Fall as Papademos Says Preparations for Greece to Exit Euro Considered -DJ
Create E-mail Alert Related Categories
RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
